

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 575)**

## **Voluntary Operational Update**

### **Deep Longevity's U.S. Expansion with Key Leadership Appointments Ahead of 2026 Launch**

This announcement is made on a voluntary basis by the board (the **"Board"**) of directors (the **"Director(s)"**) of Regent Pacific Group Limited (the **"Company"** and collectively with its subsidiaries, the **"Group"**) to inform the shareholders of the Company and potential investors of the following update in respect of its operations.

The Company today announced that Deep Longevity, Inc, and its subsidiary (collectively, **"Deep Longevity"**), a global leader in explainable AI-driven aging clocks and longevity science, the appointments of Dylan Kay as Chief Commercial Officer, the United States (**"U.S."**) and Luke Shaffer as Vice President of Sales, U.S., both of whom will commence employment on 1 January 2026.

The hires signal Deep Longevity's aggressive entry into the U.S., the world's largest wellness market, with commercial launch set for Q1 2026.

Mr. Kay brings more than 15 years of experience scaling enterprise health-tech and digital therapeutics platforms, most recently driving nine-figure growth at Livongo (now Teladoc Health) and OneDrop. Mr. Shaffer joins from a major corporate wellness provider where he led partnerships with Fortune 500 employers and health plans.

Together they will spearhead sales and partnership development across four high-priority segments:

- Corporate wellness and benefits programs
- Health insurers and risk-bearing entities
- Diagnostic laboratories and longevity clinics
- Premium consumer health platforms

Deep Longevity's clinically validated aging clocks – including BloodAge, EpigeneticAge, MindAge, BiometricAge, and the potential forthcoming FaceAge – deliver multi-modal, actionable insights into molecular, physiological, cognitive, and psychological aging. Deep Longevity's software as a service (SaaS)<sup>®</sup> solutions enable employers and insurers to shift from reactive sick care to measurable, personalised longevity programs proven to extend healthspan and reduce long-term costs.

*“Chronic disease now accounts for 90% of America’s US\$4.5 trillion annual healthcare spend,” said **Deepankar Nayak, CEO of Deep Longevity**. “Dylan and Luke are proven builders who have repeatedly turned emerging science into enterprise-scale impact. With their leadership, we are positioned to place deep aging clocks at the centre of America’s preventive health revolution.”*

Deep Longevity has set an ambitious goal of securing more than 50 U.S. enterprise clients by the end of 2026.

### **About Deep Longevity**

Deep Longevity, Inc, a wholly-owned subsidiary of the Company, together with its subsidiary develop explainable artificial intelligence systems that track human aging at molecular, cellular, organ and psychological levels. Deep Longevity’s patented deep aging clocks power vertical software as a service (SaaS)<sup>®</sup> solutions for consumers, physicians, and enterprises, delivering personalised recommendations proven to improve health and extend healthy lifespan. For more information, visit [www.deeplongevity.com](http://www.deeplongevity.com).

### **Media Contact**

Deep Longevity communications email: [press@deeplongevity.com](mailto:press@deeplongevity.com)

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**Regent Pacific Group Limited**  
**Jamie Gibson**  
*Executive Director*

Hong Kong, 10 December 2025

As at the date of this announcement, the Board comprises six Directors:

*Executive Director:*

Jamie Gibson (*Chief Executive Officer*)

*Non-Executive Directors:*

James Mellon (*Chairman*)

Jayne Sutcliffe

*Independent Non-Executive Directors:*

Mark Searle

Adrian Chan

Ihsan Al Chalabi